Benefits of the Newborn Screening Program
The Program screened 12,463,966 babies from October 1980 to December 2004 and identified the following disorders:
|
Disorder |
Cases |
|
PKU |
506 |
|
Primary Congenital Hypothyroidism |
5,087 |
|
Galactosemia |
171 |
|
Sickle Cell Disease* and other clinically significant Hemoglobinopathies* (Beta-0 Thal Major, E-Beta Thal, etc.) |
2,285 |
|
Hemoglobin H Disease** |
473 |
|
CAH*** |
52 |
|
Metabolic/Fatty Acid Oxidation Disorders |
685 |
|
|
|
|
Total |
9,259 |
|
* |
from 2/27/90 |
|
|
** |
from 7/96 (start of pilot) |
|
|
*** |
from 5/05 (start of pilot) |
|
Based on the known occurrence rates of these disorders, the number of diagnosed cases has been within the expected frequency rate. Efficient processing of test results and program monitoring have resulted in the initiation of treatment of these babies at a very early age.
Mean Age of Treatment, 1980 - 2004
|
Disorder |
Age (days) |
|
PKU |
10 |
|
Galactosemia |
5 |
|
Primary Congenital Hypothyroidism |
9 |
|
Sickle Cell Disease* |
55
|
|
*Since 1990 |